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A B S T R A C T
Selenoprotein P (SELENOP) is a liver-derived transporter of selenium (Se) in blood, and a meaningful
biomarker of Se status. Se is an essential trace element for the biosynthesis of enzymatically-active
selenoproteins, protecting the organism from oxidative damage. The usage of uncalibrated assays hinders the
comparability of SELENOP concentrations and their pathophysiological interpretation across diﬀerent clinical
studies. On this account, we established a new sandwich SELENOP-ELISA and calibrated against a standard
reference material (SRM1950). The ELISA displays a wide working range (11.6–538.4 µg/L), high accuracy
(2.9%) and good precision (9.3%). To verify whether SELENOP correlates to total Se and to SELENOP-bound
Se, serum samples from healthy subjects and age-selected participants from the Berlin Aging Study II were
analyzed by SELENOP-ELISA and Se quantiﬁcation. SELENOP was aﬃnity-puriﬁed and its Se content was
determined from a subset of samples. There was a high correlation of total Se and SELENOP concentrations in
young and elderly men, and in elderly women, but not in young women, indicating a speciﬁc sexual dimorphism
in these biomarkers of Se status in young subjects. The Se content of isolated SELENOP was independent of sex
and age (mean ± SD: 5.4 ± 0.5). By using this calibrated SELENOP-ELISA, prior reports on pathological
SELENOP concentrations in diabetes and obesity are challenged as the reported values are outside reasonable
limits. Biomarkers of Se status in clinical research need to be measured by validated assays in order to avoid
erroneous data and incorrect interpretations, especially when analyzing young women. The Se content of
circulating SELENOP diﬀers between individuals and may provide some important diagnostic information on
Se metabolism and status.
1. Introduction
Selenium (Se) is an important micronutrient in our diet, essentially
required for the biosynthesis of selenoproteins [1,2]. Selenoproteins
comprise a number of important and essential members, implicated in
the antioxidative defense and control of redox-dependent pathways
[1,3,4]. The Se status currently is a poorly deﬁned concept describing
the degree of bioavailable Se for selenoprotein biosynthesis with the
help of Se-responsive biomarkers [5]. Two hierarchical principles
govern selenoprotein biosynthesis in times of limited Se supply [6],
safeguarding that the most essential selenoproteins are preferentially
synthesized over so-called housekeeping selenoproteins [7], and that
the survival-relevant tissues are protected from Se deﬁciency [8]. This
serves to minimize adverse health consequences of an insuﬃcient
dietary Se supply so that brain and some endocrine organs (e.g. testes,
bone or thyroid) are protected from Se loss and maintain a suﬃciently
high selenoprotein biosynthesis rate essential for their proper function-
ing. Relative to brain and endocrine tissues, the liver appears to reside
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low in the hierarchical order of preferentially supplied tissues, despite
being the principle site for converting nutritional organic and inorganic
selenocompounds into an easily accessible and detoxiﬁed serum
transport protein readily available to target tissues [9]. To this end,
hepatocytes express high levels of selenoprotein P (SELENOP [10];
previously abbreviated as SEPP1, SELP or SePP), which is secreted into
the blood and is taken up by target cells via interaction with members
of the lipoprotein receptor-related protein (LRP) family, namely LRP2
(megalin) and LRP8 (APOER2) [9]. The open reading frame of human
SELENOP mRNA contains 10 in frame UGA triplets specifying
selenocysteine (Sec) insertion.
Insertion of Sec into the primary structure of selenoproteins during
translation is accomplished by a tight interplay of several trans- and
cis-acting factors; a) the UGA codon in the open reading frame, b) a
characteristic stem-loop structure in the 3′ untranslated region, which
is called the Sec-insertion sequence (SECIS) element, c) a SECIS
binding protein (SECISBP2), d) a speciﬁc elongation factor
(EEFSEC), e) the Sec-speciﬁc tRNA (TRU-TCA1-1) and f) additional
translation factors [1]. Inherited defects in the SECISBP2 gene cause a
multifaceted disease syndrome including reduced biosynthesis and
concentrations of SELENOP [11].
The two diﬀerent isoforms of the TRU-TCA1-1 gene product
tRNA[SerSec] are methylated, or not, at the anticodon wobble position
U34. This inﬂuences the hierarchical principles governing selenopro-
tein biosynthesis in times of Se deﬁciency. Methylation occurs when Se
supply is suﬃciently high, while the non-methylated form prevails
under Se-deﬁcient conditions. The biosynthesis of non-essential sele-
noproteins is mainly supported by the methylated tRNA[SerSec], which
explains why their expression correlates with Se status [12]. The
ﬁnding that liver does not belong to the preferentially supplied organs,
and that SELENOP is not an essential selenoprotein, collectively
explain why hepatic SELENOP biosynthesis and circulating
SELENOP levels constitute a reliable Se-responsive biomarker of Se
status over a wide range of Se intakes [13].
SELENOP concentrations in blood thus provide an insight into the
systemic transport and Se status as well as the hepatic selenoprotein
biosynthesis rate of an individual. However, quantiﬁcation of
SELENOP is challenging, and reported serum concentrations of
SELENOP diﬀer considerably between assays and research labora-
tories. Recently, the following concentrations of SELENOP in serum or
plasma of healthy subjects have been reported: 6.7 (5.3–9.1) µg/L in a
Turkish [14], 362.0 (252.5–694.5) µg/L in a South Korean [15], 5.3 ±
1.1 mg/L in a Japanese [16], and 52.3 ± 39.1 mg/L in a Chinese/
Australian study [17]. These concentration ranges diﬀer by almost 4
orders of magnitude, highlighting that there is an urgent need for a
better characterization and calibration of SELENOP assays used in
clinical analyses, and a need for a uniformly accepted reference
material.
The majority of analytical studies have demonstrated that, depend-
ing on overall Se status, SELENOP accounts for the largest fraction of
Se in blood. However, there are indications that the circulating
SELENOP is not a homogenous protein. Variants of diﬀerent molecular
weight have been described [13,18], in relation to genotype, premature
translational termination, limited posttranslational proteolysis or par-
tial replacement of Sec by Cys [19–22].
To allow a more precise quantiﬁcation and better characterization
of SELENOP in human blood, we have developed a new immunoassay
using monoclonal antibodies (mAb) and characterized the test accord-
ing to highest standards of laboratory-developed assays including a
calibration against the Standard Reference Material SRM1950 of the
National Institute of Standards and Technology (NIST SRM1950). Our
results indicate that gender and age aﬀect the correlation between total
Se concentrations in serum and circulating SELENOP concentrations.
By using the new mAb for immuno-aﬃnity puriﬁcation, we succeeded
in isolating SELENOP from a set of human serum samples and
determined the average Se content, which diﬀered between individuals
and was considerably below the predicted number of ten Se atoms per
molecule of SELENOP.
2. Materials and methods
2.1. Human and mouse serum samples
The animal experiment from which samples were analyzed in this
study has been described earlier [23]. The human serum samples were
from participants of the Berlin Aging Study II (BASE-II), a multi-
disciplinary project investigating medical, physical, cognitive, and
social conditions related to “healthy” and”unhealthy” aging (cohort
2). The BASE-II study population consisted of about 2200 study
subjects aged 60–80 years (elderly group) and 20–35 years (younger
group) at baseline recruitment from the greater metropolitan area of
Berlin, Germany [24,25]. All participants had given written informed
consent, and the study had been approved by the Ethics Committee of
the Charité- Universitätsmedizin Berlin, Germany (no. EA2/029/09).
Additional high quality human serum samples from healthy subjects
(cohort 1) were obtained from a commercial supplier (in.vent
DIAGNOSTICA GmbH, Berlin).
2.2. Expression of recombinant human SELENOP
Recombinant human SELENOP was expressed in baculovirus-
infected insect cells. High eﬃcient biosynthesis was achieved after
replacement of the Sec codons with cysteine codons via gene synthesis
(Euroﬁns Genomics GmbH, Ebersberg, Germany). The synthetic read-
ing frame was inserted into the baculovirus transfer vector pFastBac1
(Thermo Fisher Scientiﬁc, Karlsruhe, Germany), transformed into
competent E.coli cells and recombinant bacmid DNA were isolated.
Sf9 insect cells were transfected with bacmid DNA for obtaining a
recombinant virus stock that was used to initiate SELENOP biosynth-
esis in “High Five” insect suspension cells. Cell culture supernatant was
harvested 48 h after infection, and SELENOP was isolated by aﬃnity
chromatography on Ni-NTA agarose according to the manufacturer's
instructions (Qiagen GmbH, Hilden, Germany).
2.3. Immunization and puriﬁcation of antibodies
Monoclonal antibodies (Ab) were generated essentially as described
[26]. In brief, three female BALB/c mice were immunized with an
emulsion of puriﬁed recombinant SELENOP in TiterMax® Gold
adjuvant (Sigma-Aldrich Corp., St. Louis, U.S.A.), followed by a second,
third and fourth injection after 30, 60 and 61 days. The protocol had
been approved by the local authorities (LAGeSo Berlin, permit No. H
0331/12). The antibody-titer of the mice was determined by an indirect
ELISA on day 62 with immobilized recombinant SELENOP and pc
rabbit anti-mouse Ab (Z109, Dako Deutschland GmbH, Hamburg,
Germany) as detection antibody. The mouse showing the highest anti-
SELENOP titer was killed, the spleen removed, lymphocytes isolated,
and fused with immortalized murine myeloma cells (PAI, RRID:
CVCL_Z070) by PEG1500 (Roche Diagnostics GmbH, Penzberg,
Germany).
A macrophage cell suspension was prepared from the abdominal
cavity of a mouse as “feeder cells”. Fused hybridoma cells were
cultivated ﬁrst in HAT-DMEM-selection-medium followed by HT-
DMEM-medium on a “feeder” cell layer. After ten days, the hybridoma
culture supernatant was screened for Ab production, and productive
hybridomas with high proliferation grade and Ab titers were expanded,
cloned by limiting dilution and subcloned in DMEM medium contain-
ing 10% horse serum, 4 mM L-glutamine, 1 µg/mL fungizone, 100 U/
mL penicillin, 100 µg/mL streptomycin and 1 mM pyruvate. Eight
selected mAb were puriﬁed on a ProsepG-column (Merck Millipore,
Darmstadt, Germany) and stored at 4 °C in PBS, pH 7.4.
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2.4. Development and validation of a SELENOP-ELISA
The eight candidate Ab were adsorbed to the surface of polystyrene
plates as capture-Ab, and another aliquot was labeled with biotin for
use as detection-Ab. All 8×8 possible sandwich-assay Ab combinations
along with a SELENOP-speciﬁc polyclonal sheep Ab were tested with a
serially-diluted human serum (Supplemental Table 1). Immuno-reac-
tive SELENOP from the sample was bound by the capture-Ab. The
detection Ab was added after a 3-fold wash step and bound to the
capture-Ab-SELENOP complex. After washing, a Streptavidin-POD-
conjugate (F. Hoﬀmann-La Roche AG, Basel, Switzerland) was incu-
bated. The detection reaction was started by adding a tetramethylben-
zidine containing substrate solution (Diarect AG, Freiburg, Germany)
after a ﬁnal wash step. The reaction was stopped by the addition of
sulfuric acid, and the detection complex concentrations were quantiﬁed
at 450 nm.
The assay calibrator was prepared by pooling of 30 individual sera
of healthy U.S. citizens (Interstate Blood Bank Inc., Memphis,
TN38134, U.S.A). The sera were thawed, pooled in equal ratio and
ﬁltered through a 0.2 µm Supor® membrane (Pall GmbH, Dreieich,
Germany). According to FDA guidelines, eight calibrators and three
controls were generated. Two of the eight calibrators are anchor points
which improve the 4PL-logistic-curve-ﬁtting. These anchor points were
above the highest (ULOQ – upper limit of quantitation; 793.7 µg/L)
and below the lowest (LLOQ – lower limit of quantitation; 5.4 µg/L)
standard concentration. The working range of the standard curve was
covered by six calibrators with 12.0, 25.4, 51.7, 107.3, 215.5 and
398.4 µg/L SELENOP. Three controls were chosen from the upper
(262.2 µg/L), middle (63.8 µg/L) and lower region (14.7 µg/L) of the
quantiﬁcation range. An international standard was used to ensure the
traceability of the calibration procedure (NIST SRM1950 Standard
Reference Plasma, National Institute of Standards and Technology,
Gaithersburg, U.S.A).
The assay performance parameters speciﬁcity, accuracy, precision,
sensitivity, parallelism, and stability were determined with human
serum. To determine the stability of the analyte, three serum samples
were used directly and after dilution (1:21 in sample buﬀer). The
samples and dilutions, respectively, were incubated at 2–8 °C (regular
fridge stability), at 23 °C (bench-top stability), at 37 °C (body tem-
perature stability) and at 50 °C over a period of up to 48 h. Aliquots
(50 µL each) were incubated for 1, 2, 8, 24 and 48 h, and frozen at
−80 °C at the end of the incubation period. All samples were then
thawed and measured in parallel, in agreement with the guidelines of
the Expert Working Group of the International Conference on
Harmonisation (ICH). The limit of stability was set at 90–110%
recovery of the starting concentration (“acceptance criteria”). The limit
of stability is marked by the intersection of the 95% conﬁdence interval
with the recovery limit. The Table Curve® 2D software (Systat Software
GmbH, Erkrath, Germany) was used to describe the non-linear mean-
and conﬁdence-interval trends. For curve-ﬁttings, the simple non-
linear equations with the best regression factor r2 were used. Stability
upon freezing and thawing was determined with three undiluted serum
samples. The samples were thawed at RT for 30 min, 50 µL were
removed and transferred to an extra tube, labeled with “0” and frozen
at −80 °C. After 24 h, the samples were thawed again, another set of
50 µL samples were taken, labeled and stored at −80 °C. This proce-
dure was performed 5 times in total over a period of 5 days. All samples
were ﬁnally analyzed by the SELENOP-ELISA in one run.
2.5. HepG2 cell culture, RNA isolation, and real-time PCR
HepG2 cells were seeded at 2×106 cells per well in 6-well plates (TPP
Techno Plastic Products AG, Trasadingen, Switzerland) and cultivated at
37 °C and 5% CO2 in DMEM/F12 (Gibco, Thermo Fisher Scientiﬁc Inc.)
+10% FCS (Biochrom GmbH, Berlin, Germany). The medium was ex-
changed at 80% conﬂuency after 24 h, and cells were further cultivated for
24 h either in serum-free DMEM/F12 or DMEM/F12 containing 10% FCS.
On the third day, a concentration range of sodium selenite (1 nM–10 µM,
f.c.) was prepared in serum-free or FCS-containing medium, and treatment
was started for additional 24 h by exchanging the medium. Then, cells were
harvested, total RNA was isolated using Aurum™ Total RNAMini Kit (Bio-
Rad Laboratories, Inc, Hercules, California, U.S.A.) and ﬁrst-strand cDNA
was synthesized using iScript™ cDNA Synthesis Kit (BioRad). Relative
transcript levels of SELENOP (forward primer: 5´-TATGATAGATGTG
GCCGTCTTG−3´; reverse primer: 5´-TGTGATGATGCTCATGATGGTA-
3´) were determined using the ABsolute QPCR SYBR Green Fluorescein
Mix (Thermo Fisher Scientiﬁc) and beta actin (ACTB; forward primer: 5´-
CACCACACCTTCTACAATGAGC−3´; reverse primer: 5´-CAGAGGCGTAC
AGGGATAGC-3´) as housekeeper for normalization.
2.6. LDH-measurement
As an indicator of cell damage, the release of lactate dehydrogenase
(LDH) into the medium was determined using the Pierce LDH
Cytotoxicity Assay Kit (Thermo Fisher Scientiﬁc).
2.7. Western blot analysis
SDS-PAGE was performed using 10% Bis-Tris gels in combination
with a MOPS SDS running buﬀer as described in [27]. The samples
were prepared in LDS sample buﬀer (Thermo Fisher Scientiﬁc) with
DTT (Sigma-Aldrich). The proteins were blotted onto a 0.2 µm PVDF
membrane (Thermo Fisher Scientiﬁc) in Bicine-Tris transfer buﬀer
containing methanol. PonceauS (Sigma) was used for the visualization
of the membrane-bound proteins. SELENOP was detected using anti-
human SELENOP antibodies (InVivo, Hennigsdorf, Germany) and a
polyclonal sheep anti-mouse IgG-HRP (GE Healthcare GmbH, Munich,
Germany) in combination with the ECL Western Blotting Detection
Reagents and Hyperﬁlm™ (GE Healthcare GmbH).
2.8. Selenium analysis of blotted proteins
PonceauS-stained protein bands were excised using a 3 mm Harris
Uni-Core™ stainless steel cutting tip (Agilent Technologies, Santa
Clara, California, U.S.A.). Recovery of the proteins from the PVDF
membrane was achieved by a detergent-based protocol according to
Simpson et al. [28]. Each excised band was placed in a microtube,
mixed with 50 µL elution buﬀer (50 mM Tris-HCl, pH 9.0, containing
2% SDS, 1% Triton X-100% and 0.1% DTT) and incubated overnight at
37 °C in a Thermomixer (Eppendorf AG, Hamburg, Germany). The
tubes were centrifuged in a microfuge for 10 min at 10,000×g at
ambient temperature, and the supernatants were analyzed by total
reﬂection X-ray ﬂuorescence spectroscopy (TXRF) using an S2
PICOFOX device (Bruker Nano GmbH, Berlin, Germany). Gallium
(Alfa Aesar GmbH & Co KG, Karlsruhe, Germany) was used as internal
standard, and the gallium-sample-mixtures were applied to quartz
carriers and dried for 1 h at 50 °C before being analyzed. Detergent
containing samples were applied to silicon coated carrier for the TXRF
analysis.
2.9. Aﬃnity chromatography of human SELENOP
A SELENOP-speciﬁc antibody (clone mAb2, expanded by InVivo,
Henningsdorf) was coupled to aldehyde-activated agarose beads
(AminoLink® Plus Coupling Resin, Thermo Fisher Scientiﬁc) according
to the manufacturer's instructions (1.3 mg Ab2 per mL column bed).
Serum or plasma samples, 35 mL each, were diluted 1:2 with binding
buﬀer (PBS, pH 8.0) and ﬁltered through a Supor® PES membrane with
0.8 µm pore size (Pall GmbH). The ﬁltrate was incubated with the
column bed overnight in batch at 4 °C using a rotary shaker, and then
transferred to an empty column. The ﬂow-through was collected, and
the column bed was washed ﬁve times with 10 mL binding buﬀer.
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Elution was achieved stepwise with citric acid (50 mM, pH 2.0), and
eluates were neutralized by 1 M Tris, pH 9.0. The ﬂow through, wash
and the eluate were collected and analyzed by SELENOP-ELISA.
2.10. Immuno-aﬃnity puriﬁcation of SELENOP from human sera in
a 96-well format
The SELENOP-speciﬁc antibody mAb2 (expanded and puriﬁed by
InVivo) was coupled to agarose beads and used for immuno-aﬃnity
puriﬁcation of SELENOP from a set of human samples. To this end, a
96-well sandwich combination consisting of a ﬁlter plate and a
polypropylene plate was ﬁlled with 25 µL column bed equivalent to
25 µg antibody per well. Each puriﬁcation step was performed for
10 min on an orbital shaker at 650 rpm followed by centrifugation at
22 °C and 1,000×g for 1 min. Forty serum samples (à 100 µL) from the
BASE-II study plus a control serum were applied in duplicates and
incubated overnight at 4 °C. Three wash steps à 200 µL PBS, pH 7.4,
followed. Bound SELENOP was eluted by 2×25 µL citric acid (50 mM,
pH 2.0). The combined eluate per sample (50 µL) was neutralized by
5 µL Tris (1 M, pH 9.0) and analyzed by TXRF and SELENOP-ELISA.
The accuracy of the TXRF-measurement was veriﬁed by the trace
element standard Seronorm™ Trace Elements Serum L-2 (Sero AS,
Billingstad, Norway) on three diﬀerent days. The measured Se con-
centration (mean ± SD: 164 ± 14.1 µg/L) was within the required
reference range (143–183 µg/L) of lot number 0903107.
2.11. Statistical analysis
Biostatistical analyses were performed by the GraphPadPrism®
Software Version 6.04 (GraphPad Software, Inc., San Diego, U.S.A.).
The D′Agostino-Pearson omnibus test was used to test for normal
distribution, and comparisons of normally-distributed values were
achieved with an unpaired t-test or one-way ANOVA. Pearson´s
correlation coeﬃcients were calculated to analyze associations between
two parameters. IBM® SPSS® Statistics, Version 22 (IBM Corp.,
Armonk software) was used for linear regression analyses. The
signiﬁcance of the results was expressed as the P-value (two-tailed)
which is interpreted as followed: P < 0.0001 # and P < 0.001*** are
extremely signiﬁcant, P < 0.01** is very signiﬁcant, P < 0.05* is sig-
niﬁcant and P≥0.05 is not signiﬁcant. The software Table Curve® 2D
Version 5.01 (Systat Software GmbH, Erkrath, Germany) was used for
the precision proﬁle (Fig. 4), and for the non-linear curve ﬁtting in the
stability results (Fig. 5).
3. Results
3.1. Establishment, characterization and calibration of a SELENOP-
speciﬁc ELISA
Recombinant Sec-free human SELENOP was expressed in insect
cells, puriﬁed and used for the immunization of mice. Hybridoma cells
were generated essentially as described [26], and screened for
SELENOP-reactive antibodies (Ab). Eight most productive and stable
hybridoma cell lines were expanded and the monoclonal Ab were
puriﬁed by protein chromatography. All of the eight newly generated
Ab recognized human SELENOP in Western blot analyses without any
cross-reactivity to the bovine selenoprotein present in FCS. For
comparison, a formerly established SELENOP-speciﬁc polyclonal
sheep Ab (pAb) and the reference assay (Ref) were included [29],
and all nine Ab were tested in combination for signal strength and
linearity in a sandwich-assay format (Supplemental Table 1). The
highest sensitivity was achieved when the newly generated SELENOP-
speciﬁc monoclonal Ab5 was immobilized as capture-Ab, and either
mAb2, mAb3, mAb4, mAb7 or mAb8 were used as detection-Ab. For
reasons of stability, aﬃnity and yield after scale-up, ﬁnally mAb2 was
selected as the detection-Ab of choice for the establishment of the novel
SELENOP-ELISA.
3.2. Characterization of the speciﬁcity of the antibodies used for
SELENOP-ELISA
The ELISA signal for quantiﬁcation requires the binding of detec-
tion mAb2 to its antigen SELENOP. To test whether mAb2 recognizes
native human SELENOP directly in serum or plasma, an immuno-
aﬃnity column was prepared with mAb2 and used to purify SELENOP
from human serum and plasma. The eluates were analyzed via
SELENOP-ELISA, concentrated by acetone precipitation, and sepa-
rated by SDS-PAGE. The preparations contained 8.3 μg and 10.4 µg
SELENOP in total, respectively, and were transferred to a polyvinyli-
dene diﬂuoride (PVDF) membrane. After staining with PonceauS,
diﬀerent bands were visible and were excised with a cutter (Fig. 1A).
The identity of the excised protein was determined by N-terminal
Edman amino acid sequencing (Proteome Factory AG, Berlin,
Germany). The human SELENOP-speciﬁc peptide sequence ESQDQS
was identiﬁed at the molecular weight mark of 50 kDa, verifying the
identity of the excised band and conﬁrming the suitability of the
antibody mAb2 for SELENOP puriﬁcation by immuno-aﬃnity chro-
matography.
Deﬁned spots of the stained membranes were identiﬁed, cut out
and isolated (Fig. 1A). Trace element analysis by total reﬂection X-ray
ﬂuorescence (TXRF) was performed as a second test for characterizing
the immuno-aﬃnity-puriﬁed SELENOP. Proteins were eluted from the
excised membrane spots and Se contents were determined (Fig. 1B). In
the SELENOP preparation from plasma, the highest Se concentration
was identiﬁed at 50 kDa (not shown). Two separate immuno-reactive
bands were visible in the preparation of SELENOP from serum after
Fig. 1. Characterization of aﬃnity-puriﬁed SELENOP by Western blot and trace element
analysis. (A) PonceauS stained PVDF-membrane of a preparation of SELENOP from
human serum after separation by SDS-PAGE (L1). Several discrete protein bands were
visible, and were cut out along with membrane control samples as protein/PVDF
membrane spots (L2). (B) Spots were eluted and analyzed by TXRF for quantiﬁcation
of Se contents (spots 1–22; B denotes the pure elution buﬀer); mean ± SD, n=2
determinations per sample. (C) Western Blot of the aﬃnity-puriﬁed SELENOP with
the detection antibody mAb2 (L3; 3.0 ng, and L4; 1.5 ng of puriﬁed SELENOP).
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SDS-PAGE and blotting, migrating at 54 and 48 kDa in our SDS-PAGE
system (Fig. 1C). The spots #12 and #13 displayed highest Se
concentrations, corresponding in size to the immuno-reactive
SELENOP bands in the Western blot analysis.
As a second test for speciﬁcity, HepG2 cells were incubated with
increasing concentrations of sodium selenite (Na2SeO3) in triplicates in
order to induce human SELENOP biosynthesis in a reproducible in
vitro system. Cells were cultivated under serum-free or fetal calf serum
(FCS)-containing conditions, whereby the former tended to impair
proliferation and the latter stimulated growth. Using the 4-parameter-
logistic-curve-ﬁtting model (4PL), the quantiﬁcation of SELENOP
resulted in a sigmoidal dose-response curve up to 1.0 µM selenite,
and a sharp decline at higher concentrations (10 µM selenite).
The four parameters of the 4PL-curve ﬁtting diﬀered when deter-
mined for the two in vitro selenite supplementations (Fig. 2A). In
serum-free medium, an eight-fold increase in SELENOP concentra-
tions was observed between control (47.9 µg/L) and cells exposed to
1.0 µM of selenite (392 µg/L). In FCS-containing medium, the analo-
gous increase was only ﬁve-fold (from 56.8 to 287 µg/L), and maximal
SELENOP expression was slightly lower than under serum-free condi-
tions.
The Hill coeﬃcient (Hill slope) describing the steepness of the curve is
considerably steeper under serum free conditions than in the presence of
FCS, and the half maximal eﬀective concentration (EC50) of Na2SeO3 for
SELENOP induction is lower under serum free (EC50=20.2 nM) than under
FCS-containing conditions (EC50=27.1 nM). The analysis of L-lactate
dehydrogenase (LDH) activity for detecting cytotoxic eﬀects indicated no
cell damage up to 1.0 µM of selenite (Fig. 2B). Elevated LDH-activity was
present in the medium at 10 µM selenite, indicating that a cytotoxic
concentration had been reached [30]. SELENOP transcript levels were
about two-fold higher in selenite supplemented (at 1.0 µM selenite f.c.) as
compared to control cells (no added selenite) under both serum-free and
serum-containing conditions (Fig. 2C).
In order to further test the speciﬁcity of the SELENOP-ELISA,
serum samples from wildtype (Selenop+/+) and homozygous Selenop
knockout mice (Selenop-/-) were analyzed along with samples from
knockout mice speciﬁcally expressing a human SELENOP transgene in
liver (Selenop-/-tg) [31]. Six samples per genotype (three male and three
female mice) were analyzed, and immuno-reactive SELENOP was
detected only in mice expressing the human transgene (0.8 ± 0.2 mg/
L SELENOP, mean ± SD), but not in serum samples from Selenop+/+ or
Selenop-/- mice (Fig. 2D).
3.3. Determination of a typical standard curve and precision proﬁle
of the SELENOP-ELISA
The serum standards used in the SELENOP-ELISA were calibrated
against the NIST Standard Reference Material SRM1950 [32].
Calibration was carried out on three days with two operators in four
replications. The standards were evaluated using a serial dilution of
SRM1950 in sample buﬀer of 1:8 to 1:1024. The SELENOP concentra-
tion (c SELENOP) of the reference plasma was calculated at 4.44 mg/L
using the following equation:
Fig. 2. Speciﬁcity of the ELISA for human SELENOP expressed in vitro or in mice. All values are means ± SD of biological triplicates (A–C) or 6 animals (D). (A) Increasing SELENOP
concentrations are measured by the ELISA at 24 h after adding sodium selenite to the culture medium of HepG2 cells. Response curves and maximum levels diﬀer between cells grown in
the presence or absence of 10% FCS. (B) LDH activity in medium indicates cytotoxic eﬀects at 10 µM of selenite. (C) SELENOP mRNA concentrations increase moderately in response to
selenite in the concentration range of 1.0 nM to 1.0 µM. (D) The SELENOP-ELISA does not detect murine Selenop in wildtype (wt) or Selenop-knock out (ko) mice, but quantiﬁes human
SELENOP expressed from an albumin-promotor driven transgene (tg).
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For this calculation, the following data were used; a SELENOP-
related Se concentration of 50.2 µg/kg (c Se), a plasma density of
1.028 kg/L (ρ plasma), an average molecular weight of SELENOP of
51,000 g/mol (MW SELENOP) and of Se of 78.96 g/mol (MW Se), and
an average Se content of SELENOP of 7.5 atoms of Se per SELENOP, as
determined in rat [33].
The precision proﬁle (Fig. 3B) determines the dynamic (working) range
of the standard curve (Fig. 3A). Three operators measured on three days in
two diﬀerent laboratories with two plates per day in four replications each
standard of the standard series. The mean and the coeﬃcient of variation
(CV) of each concentration in these 18 determinations were calculated.
SELENOP concentrations were plotted on the X-axis and the CV value on
the Y-axis. A non-linear function with the highest regression factor was
generated by the software TableCurve® and yielded the following result;
r2=0.996; equation: y=a+bx+c/x+dx2+e/x2+fx3+g/x3; a=−482.6; b=182.2;
c=699.9; d=−36.0; e=−513.9; f=3.36; g=158.4. Fig. 3B shows the intersec-
tion points of the two horizontal lines at 10% and 20% CV with the
precision proﬁle. The intersection points at 10% and 20% CV were
calculated by using the non-linear equation. The lower limit of quantiﬁca-
tion (LLOQ) was determined at a SELENOP concentration of 11.6 µg/L,
and the upper limit of quantiﬁcation (ULOQ) at 538.4 µg/L, thereby
deﬁning the working range at SELENOP concentrations between 11.6
and 538.4 µg/L. The intersection at 20% CV deﬁnes the limit of detection
(LOD), and was reached at a SELENOP concentration of 6.7 µg/L.
3.4. Determination of the accuracy (trueness) and precision of
SELENOP-ELISA
Three diluted control sera with diﬀerent SELENOP concentrations
in the lower (14.7 µg/L), middle (63.8 µg/L) and upper (262.2 µg/L)
calibrator concentration range of the standard curve were determined
by three operators with two plates per operator on three days. The
controls were analyzed four times per plate. The average deviation of
the closeness of the measured SELENOP concentrations to the nominal
reference SELENOP concentration was +2.9% (operator 1; −0.4%,
operator 2; +9.6%, operator 3; −0.4%).
The closeness of individual determinations of the same sample
(precision) was measured at three levels. The repeatability within one
plate (intra-assay precision), the reproducibility (inter-assay precision)
and the intermediate precision (variation between two laboratories)
were determined with three operators (2 plates per operator) on three
days in two diﬀerent laboratories. Six serum samples were analyzed six
times per plate. The mean within one plate variation was determined at
6.2% CV (operator 1; 6.2%, operator 2; 6.6%, operator 3; 5.7%), the
inter-assay-variation was 10.5% CV (laboratory 1; 11.1%, laboratory 2;
9.9%), and the variation between two laboratories were determined as
11.3% CV, resulting in an average precision of 9.3%.
3.5. Parallelism and recovery of SELENOP in diﬀerent human
matrices
Serial dilutions in sample buﬀer within the working range of the
standard curve of ﬁve matrix-matched serum as well as EDTA-, Na-
citrate- and Li-heparin-plasma samples were tested in duplicates. The
back-calculated concentrations were all within 20% of the nominal
concentration (Supplemental Table 2). This result justiﬁes the choice of
the NIST reference plasma consisting of a Li-heparin matrix as a
suitable calibration sample for the serum standards of the SELENOP-
ELISA, and the recommendation to its acceptance as a universal
reference material for calibrating quantiﬁcation methods of
SELENOP from human samples.
Next, the SELENOP concentrations in 54 matrix-matched serum
and citrate-plasma samples were determined. A correlation analysis
and an unpaired t-test indicate that the matrices yield highly correlat-
ing but diﬀerent values (Pearson´s correlation factor, two-tailed:
r=0.909, P < 0.0001; mean ± SD, serum: 4.0 ± 0.9 mg/L; versus ci-
trate-plasma: 3.4 ± 0.8 mg/L). Therefore, caution is advised when
including samples of diﬀerent matrices into the same analysis.
3.6. Stability of SELENOP in human serum
The stabilities of three serum samples and dilutions in sample
buﬀer were compared over a period of 1, 2, 6, 24 and 48 h. Linear
regression analyses were performed when 80% of the measured values
fell into the 90–110% acceptance range. The recovery showed a
positive trend upon storage at 2–8 °C (Fig. 4A). Within one hour at
2–8 °C, the conﬁdence interval was surpassed to an unacceptable
degree. Therefore, immediate storage of serum in the refrigerator for
subsequent analysis in the SELENOP-ELISA is not recommended. The
"benchtop" stability was determined at ambient temperature (Fig. 4B),
and indicated that undiluted serum samples are stable for at least 24 h
at 23 °C. At higher temperatures of 37 °C (Fig. 4C) or 50 °C (Fig. 4D),
the measured recoveries intersected the conﬁdence interval at 19.2 min
(37 °C) and 8.5 min (50 °C), respectively, indicating a limited stability
of SELENOP at elevated temperatures in undiluted serum. As the
samples are routinely diluted prior to analysis in sample buﬀer, we
tested SELENOP recovery in diluted samples (1:21, vol: vol) upon
prolonged storage times at the diﬀerent temperatures as described
above. Both in the refrigerator (Fig. 4E) and at ambient temperature on
the benchtop (Fig. 4F), the diluted samples showed an acceptable
recovery of SELENOP during a time period of up to 48 h. In
Fig. 3. Standard curve and precision proﬁle of the SELENOP-ELISA. (A) The intersections of the horizontal line of the precision proﬁle at 10% CV limit the working range with the
concentrations of the LLOQ and the ULOQ. Concentrations below or above are anchor points for curve ﬁtting. (B) The intersection of the horizontal 20% CV-line generates the LOD;
determined on separate days by three operators in two diﬀerent laboratories.
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comparison, recovery dropped below an acceptable level upon incuba-
tion at 37 °C for > 2 h (Fig. 4G). Human samples containing SELENOP
can thus safely be stored for days in dilution buﬀer in the refrigerator
before analysis. Finally, several rounds of freezing were tested. Despite
yielding an increasing deviation from the starting concentration,
SELENOP recovery stayed within acceptable limits even after three
cycles of freezing and thawing (Fig. 4H).
3.7. Correlations of Se and SELENOP concentrations in male and
female serum
Se and SELENOP concentrations in human serum do correlate well
but not perfectly. In order to test the interrelation and obtain high
quality serum samples, a blood donation was commissioned by a
commercial provider. The processing of blood to frozen serum was
performed within 4 h by close adherence to a deﬁned pre-analytical
procedure. Hereby, serum samples from 99 healthy Caucasian subjects
(43 men, age range 18–64 y; 56 women, age range 18–55 years) were
obtained and analyzed (Table 1). The mean ± SD concentrations of Se
(male; 77.5 ± 14.1 vs. female; 80.0 ± 12.5 µg/L; P=0.422) and
SELENOP (male; 4.3 ± 1.0 vs. female; 4.2 ± 0.7 mg/L; P=0.432) were
not signiﬁcantly diﬀerent between the sexes. In both sexes, a signiﬁcant
positive correlation of Se and SELENOP was observed (P < 0.0001). A
linear regression model (model 1) was used to determine the sex-
speciﬁc impact of Se on SELENOP concentrations. For men, 58% of the
variance in SELENOP-concentrations were explained by Se, while it
was 32% for women (adjusted R2). The regression coeﬃcient B
indicates the change of the dependent variable (SELENOP) by the
factor (Se). Increasing Se by 10 µg/L increased SELENOP by 0.52 mg/
L in men and by 0.35 mg/L in women, respectively.
On this account, the inﬂuence of Se and age on the linear model was
investigated (model 2). For men, age elicited no eﬀect (P=0.664), while
for women, age was close to having a signiﬁcant impact (P=0.068). Se
and age accounted for 35% of the variance in SELENOP concentrations
in women, with Se (10 µg/L) being the stronger (standardized regres-
sion coeﬃcient, Beta=0.569) and age (10 years) the weaker factor
Fig. 4. Stability of human SELENOP. Three serum samples were tested undiluted (A–D) and as dilutions in sample buﬀer (E–G). (A) Storage at 2–8 °C caused an increase in SELENOP
recovery already after 1 h. (B) Recovery was within acceptable limits after storage at ambient temperature for 25.9 h. Incubations at higher temperatures of (C) 37 °C, or (D) 50 °C
caused a rapid decline of recovery. (E) In comparison, diluted SELENOP samples were more stable and showed an acceptable recovery at 2–8 °C over the full time period. (F) At 23 °C,
recovery was acceptable for up to 28.9 h. (G) At 37 °C, SELENOP recovery dropped more than 10% after 2.2 h. (H) Undiluted serum samples yielded acceptable SELENOP recovery after
undergoing up to three freeze-thaw cycles.
S. Hybsier et al. Redox Biology 11 (2017) 403–414
409
(Beta=0.203). An increase in Se by 10 µg/L was associated with an
increase in SELENOP by 0.34 mg/L (B=0.034), while an increase of
10 y of age were associated with an increase of 0.16 mg/L (B=0.016).
In order to test these ﬁndings in a second independent cohort with
a closer examination of the inﬂuence of age, high quality serum
samples were analyzed from young (22−26 y) and elderly (73−79 y)
men and women (n=10 per group) participating in the Berlin Aging
Study II (BASE-II) [24,25]. Again, compared to cohort 1 both Se (male;
61.2 ± 17.8 vs. female; 64.3 ± 8.9 µg/L; P=0.491) and SELENOP (male;
4.1 ± 1.2 vs. female; 4.0 ± 0.7 mg/L; P=0.720) concentrations did not
diﬀer between the sexes. The linear regression model 1 showed that
91% of the variance in SELENOP concentrations was attributable to Se
in men (Beta=0.956, P < 0.0001), but that only 36% of SELENOP
variance were attributable to Se in women (Beta=0.628, P=0.003,
Table 1). An increase in Se by 10 µg/L were associated with a
SELENOP increase of 0.64 mg/L in males, and 0.47 mg/L in females,
respectively.
Including the cofactor age into the linear regression (model 2), a
signiﬁcantly higher proportion of SELENOP variance could be ascribed
to Se in women (adjusted R2=0.705), whereas age had no eﬀect in men.
In women, Se was contributing to SELENOP variance with a standar-
dized regression coeﬃcient beta of 0.655 (P < 0.0001), and age with
0.585 (P < 0.0001). SELENOP increased by 0.49 mg/L (B=0.049) per
increase of Se (10 µg/L), whereas 10 y of age were associated with an
increase in SELENOP of 0.15 mg/L (B=0.015).
The relatively poor correlation of serum Se and SELENOP concen-
trations in young women may be due to a variable Se content per
SELENOP molecule. To test this hypothesis, SELENOP was puriﬁed
from male and female serum samples by aﬃnity chromatography with
mAb2- coated agarose beads. Per sample, 100 µL of serum were
incubated with 25 µL of aﬃnity column material, washed three times
and eluted into a ﬁnal volume of 55 µL (Fig. 5). Se in the original serum
(“sample load”) and the respective SELENOP preparation (“eluate”)
correlated positively (Fig. 6A, Pearson r=0.804, 95% CI 0.658–0.892).
In comparison, the SELENOP concentrations in sample load and eluate
correlated to an even higher degree (Fig. 6B, r=0.929, 95% CI 0.868–
0.962). Similarly, a high correlation is observed when comparing Se
and SELENOP in serum (“sample load”) (Fig. 6C), and an even higher
correlation when comparing both parameters in the eluates (Fig. 6D).
One way ANOVA analysis of box and whiskers plots of Se (not shown)
and SELENOP (Fig. 6E–F) showed no diﬀerences in concentrations
between the groups in both the sample load and the eluate. To calculate
the Se (MW; 78.96g/mol) to SELENOP (MW; 51,000g/mol) ratios, the
mass concentrations were converted to their molar concentrations
(nmol/L) using the speciﬁed molecular weights. The Se to SELENOP
ratio highlights a signiﬁcantly higher value in serum samples from
young females as compared to the other three groups (Fig. 6G).
Notably, this diﬀerence disappears in the eluates consisting primarily
of SELENOP (Fig. 6H). These results were also conﬁrmed in the linear
regression analysis in Table 1. In the eluates, the inﬂuence of the
female-speciﬁc cofactor age decreased to non-signiﬁcant in the linear
regression model 2 (adjusted R2=0.742, BetaSe=0.840, PSe < 0.0001,
BetaAge=0.136, PAge=0.270). In men, the inﬂuence of age remained
insigniﬁcant (adjusted R2=0.893, BetaSe=0.954, PSe < 0.0001,
BetaAge=0.015, PAge=0.851).
The age-dependent sexual dimorphism is also reﬂected in the
histogram of the frequency distribution, where the crude serum
samples (Fig. 6I) indicate a positive skewed distribution (v=0.644).
In isolated SELENOP preparations, the ratios are less asymmetrically
distributed (v=0.467) and the major frequency peak resides at 5.0–5.6
atoms of Se per molecule of SELENOP (mean ± SD: 5.4 ± 0.5; min: 4.4;
max: 6.7; Fig. 6J). A total of 43% of the examined sera reside within
and > 50% outside of this range, independent of age or sex of the
sample donor. Comparing the Se content of the SELENOP molecules in
the eluate with the total Se to SELENOP ratio in the sample load results
in 48.3 ± 5.4% (mean ± SD) of Se that is attributable to SELENOP in
the young women analyzed. In the other groups, this value is
signiﬁcantly higher (young men; 54.5 ± 5.5, elderly men; 56.1 ± 8.8,
elderly women; 56.0 ± 7.3%).
4. Discussion
In this manuscript, we report on the generation, characterization,
validation and calibration of a new ELISA, which quantiﬁes human
SELENOP. In addition, we describe a strategy for determining the Se
content of SELENOP in clinical studies, and highlight its variability
between healthy subjects. Speciﬁcity of the ELISA and the antibodies
used was veriﬁed by ﬁnding a strong correlation of SELENOP to Se
concentrations in human sera, supporting the notion that SELENOP is
a valid biomarker of Se status [34]. Further proof for its speciﬁcity was
Table 1
Linear regression analysis of Se and SELENOP in males and females.
Cohort Sex N Model Predictors Adjusted R2 B (95% CI) Beta P
1 male 43 1 Se 0.577 0.052 (0.038, 0.066) 0.766 0 #
2 Se 0.568 0.053 (0.039, 0.067) 0.771 0 #
age 0.003 (-0.012, 0.019) 0.045 0.664 ns
female 56 1 Se 0.319 0.035 (0.021, 0.048) 0.576 0 #
2 Se 0.349 0.034 (0.021, 0.047) 0.569 0 #
age 0.016 (-0.001, 0.033) 0.203 0.068 ns
2Sample Load male 20 1 Se 0.909 0.064 (0.054, 0.074) 0.956 0 #
2 Se 0.903 0.064 (0.054, 0.075) 0.956 0 #
age 0.000 (-0.007, 0.007) -0.001 0.994 ns
female 20 1 Se 0.361 0.047 (0.018, 0.077) 0.628 0.003 **
2 Se 0.705 0.049 (0.030, 0.069) 0.655 0 #
age 0.015 (0.008, 0.022) 0.585 0 #
2Eluate male 20 1 Se 0.899 0.126 (0.106, 0.146) 0.951 0 #
2 Se 0.893 0.126 (0.105, 0.148) 0.954 0 #
age 0.001 (-0.007, 0.008) 0.015 0.851 ns
female 20 1 Se 0.738 0.118 (0.084, 0.151) 0.867 0 #
2 Se 0.742 0.114 (0.080, 0.148) 0.84 0 #
age 0.004 (-0.003, 0.011) 0.136 0.27 ns
Investigating the influence of Se (model 1) and Se and age (model 2) on the linear dependence in serum (sample load) of both cohorts, and the eluate (SELENOP preparations) of cohort
2. The influence of Se on the variance of serum SELENOP-concentrations are higher in men than in women. The additional consideration of the impact of age on SELENOP showed an
influence in female but not in male subjects. This finding was very pronounced in cohort 2, which had a focus on age. The age-dependent sexual dimorphism disappeared when
SELENOP was isolated from serum (cohort 2), meaning that the Se content of the SELENOP-molecule is independent of age and sex (cohort 2, eluate). P < 0.0001 (#); P < 0.01 (**); not
significant (ns).
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obtained by monitoring sodium selenite-stimulated SELENOP bio-
synthesis from human hepatocytes. Final evidence was obtained by
analyzing serum from mice expressing a human SELENOP transgene
[31]. Comparing young and elderly male and female subjects, the
correlations between Se and SELENOP in serum turned out to be
particularly strong in young men, in elderly men and in elderly women,
but not in young women. There were no indications of an inﬂuence of
contraceptives on the circulating Se or SELENOP concentrations when
separating the women into subjects using or not-using birth control
pills. By isolating SELENOP, we realized that the Se content of
SELENOP appeared lower than predicted, not uniform in diﬀerent
subjects, and independent of age and sex. Hence, it does not account
for the relatively poor Se to SELENOP correlation in young females.
These ﬁndings add a novel level of complexity to SELENOP biology and
Se status analysis in clinical studies.
Unfortunately, until now there is no generally-accepted reference
material for human SELENOP. In order to enable comparisons across
laboratories, we have chosen the NIST reference plasma SRM1950 as
standard as it has been thoroughly characterized for its Se-containing
components [32]. With a total Se concentration of 108.5 µg/L and a
calculated SELENOP concentration of 4.44 mg/L, it is well suited to
serve as universal reference material as it lies in the same range that is
determined in several human studies [16,35,36].
This ﬁnding, however, questions the validity of studies reporting
grossly diﬀerent SELENOP concentrations in humans, as mentioned in
the introduction. It is of concern, that especially the reports on
SELENOP being strongly up-regulated in patients with diabetes
mellitus or in obese subjects used an uncharacterized commercial
assay. These studies reported average SELENOP concentrations of 0.36
in healthy, 0.87 in prediabetic and 1.03 mg/L in diabetic subjects [15],
or 14.5 in lean and 52.3 mg/L in obese subjects [17], i.e., outside a
reasonable range in relation to other studies comparing the Se status of
healthy and diabetic patients [37–40]. Even from a theoretical
consideration, assuming 50% of serum Se attributable to SELENOP
with an average of 7.5 atoms of Se per SELENOP molecule and a MW
of 51 kDa, a SELENOP concentration of 0.36 mg/L or 52.3 mg/L
would correspond to serum Se concentrations of as low as 8.8 µg/L
and as high as 1280 µg/L, respectively. Both values are outside a
reasonable dimension for healthy human subjects, especially in relation
to the congruent results from experienced scientists, who have
established quantitative tests for SELENOP determination like Hill
and Burk [41], or Saito and Takahashi [19].
The metabolism of Se, the associations of Se status with disease and
the eﬀects of Se supplementation show some sex-speciﬁc diﬀerences
[6,42]. It was therefore highly interesting to observe that the correla-
tions of Se and SELENOP concentrations diﬀer between the sexes, and
that the correlation was poorest in young women. Diﬀerences in Se
distribution to GPX3 and SELENOP and a varying Se-content in
albumin were noted before in men and women in an epidemiological
study [43]. It is reported that GPX3 is more highly expressed in healthy
females than in males [44], and that alcohol consumption increased
total Se in women but not in men [45]. Until now, however, only few
clinical studies report on both Se and SELENOP concentrations, such
as a trial which compared healthy Chinese subjects and reported a
higher correlation of Se and SELENOP in young boys as compared to
adult men [41]. A small intervention study provided evidence for a sex-
speciﬁc response of diﬀerent SELENOP genotypes to Se supplementa-
tion [46]. Similarly, upon SeMet supplementation, females appeared to
excrete higher amounts of Se in urine when compared to males,
indicative of a higher amount of excretable small selenocompounds
in blood [47]. Collectively, males and females diﬀer in a number of Se-
related parameters, and this notion has been corroborated in several
respective animal experiments highlighting pre- and posttranscrip-
tional processes as being responsible for some of the sex-speciﬁc
diﬀerences [48,49].
Very few clinical studies have analyzed gender as separate factor in
association analyses, or have speciﬁcally compared young and elderly
women. More often, speciﬁc diﬀerences are found with respect to age,
e.g., in the relation of Se and blood lipids [50]. However, menopausal
state has been described as an important factor in relation to Se status
[51]. GPX3 activity increases in parallel to estrogens during the female
menstrual cycle [52], and females express higher serum GPX3 con-
centrations than males [44]. Further speciation studies with human
serum are needed to better pinpoint the Se-containing fraction(s)
responsible for the relatively poor correlation of Se and SELENOP in
young females.
Another surprising ﬁnding relates to the average number of Se
atoms per SELENOP molecule, which can be covered by a combination
of ELISA and trace element quantiﬁcation of puriﬁed SELENOP
preparations. Theoretically, the SELENOP transcripts predict the co-
translational insertion of 10 Sec residues per molecule. The number of
UGA codons per transcript varies among the mammals, and the
predicted numbers range from 7 Sec residues per SELENOP in guinea
pig to 15 in dog [53]. Our data show that the theoretical predictions
should not be taken for granted, as done in cases when genetic
information is extrapolated to the proteins [54]. Recently, we have
shown that not all theoretical positions are fully occupied by Sec in
SELENOP isolated from healthy human subjects [20]. This can be
considered as translational relaxation or translational errors, which
have been shown to be of relevance for the function of selenoenzymes,
e.g. in response to pharmacological treatments with antibiotics of the
aminoglycoside type [55–58]. Here, we report that on average only 5.4
± 0.5 Sec residues per SELENOP molecule are present, and that a
considerable inter-individual variation exists. Again, only few studies in
the literature report on the Se content of SELENOP. In rat, an average
ratio of 7.5 Se atoms per Selenop is reported [59], while in mice the
ratio is around 5 Se atoms per Selenop molecule [60]. These results are
in agreement with our analysis from human serum, as shown above.
Fig. 5. Work-ﬂow of the 96-well-aﬃnity-chromatography procedure to isolate SELENOP from human serum samples for analysis. The samples were applied on the immuno-aﬃnity
material in a 96-well ﬁlter plate, washed and eluted. These steps were separated by a short centrifugation step for collecting the ﬂow through, wash and elution fractions. The combined
and neutralized eluates were analyzed by TXRF and SELENOP-ELISA in order to calculate the Se content per SELENOP.
S. Hybsier et al. Redox Biology 11 (2017) 403–414
411
Fig. 6. Analysis of Se and SELENOP status of young [y] and elderly [e] male [m] and female [f] participants. Forty samples (10 per group) of the BASE-II study were analyzed and
subjected to aﬃnity-chromatography via mAb for the isolation of SELENOP. (A) Se, (B) SELENOP and (C–D) Se and SELENOP concentrations were compared by Pearson correlation.
Box-and-Whiskers plots present the mean values (”+“) and 5th–95th percentiles of the SELENOP concentrations in serum (E) or in SELENOP preparations (F). (G) The Se to SELENOP
ratio in serum was signiﬁcantly higher in young women as compared to the other groups. (H) This diﬀerence was not observed when analyzing the puriﬁed SELENOP preparations. (I)
The total Se to SELENOP ratios show an asymmetric distribution across the samples, while (J) the Se to SELENOP ratios of the SELENOP preparations are less skewed distributed.
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The molecular reasons for the lower than predicted Se content of
SELENOP may be a premature translational termination at UGA
codons within the reading frame giving rise to C-terminal shortened
and Se-poor isoforms, as suggested by Ma et al. [21]. Accordingly, in
the MS/MS-based analyses of the reference plasma SRM1950 of the
U.S. population, three SELENOP molecules of 57, 49 and 45 kDa were
identiﬁed [18]. Alternatively, slightly shortened SELENOP isoforms
may result from a speciﬁc limited proteolysis within the Se-rich C-
terminus [19]. Both mechanisms would explain the relatively low Se
content of circulating SELENOP and need to be further analyzed in
detail.
Alternatively, it has been shown before that the selenoprotein
biosynthesis machinery is not always working very precisely and
incorporation errors occur, e.g., in the presence of antibiotics [55–
58]. A more relaxed precision rate would also nicely explain the overall
phenomenon that such an ineﬃcient and slow process as Sec insertion
still proceeds relatively fast despite the consecutive hurdles that are
given by a total of successive 10 UGA codons in a single reading frame,
as is the case in human SELENOP [61,62]. Other endogenous, dietary
or environmental factors may also act in a similar way to aminoglyco-
side antibiotics, causing incorporation errors speciﬁcally at UGA
codons within reading frames, i.e., during Sec insertion, and leading
to a relatively low Se content of SELENOP. Detailed analyses of
puriﬁed SELENOP preparations are thus necessary to clarify this
ﬁnding, which obviously is diﬃcult as in our previous studies, only 4
out of the 10 potential Sec positions could be successfully identiﬁed
and structurally determined by LC-MS/MS [20]. This ﬁnding may
point to truncated SELENOP isoforms not reaching the concentrations
necessary for successful identiﬁcation in the MS analyses conducted.
In conclusion, our analyses indicate a speciﬁc sexual dimorphism of
the correlation between Se to SELENOP in pre-menopausal women,
and a considerable inter-individual variation in the Se content of
human SELENOP. It remains to be tested which parameters elicit the
most intense eﬀect on the Se content of SELENOP, e.g., Se status,
genotype, selenocompound intake, epigenetic mechanisms, other he-
patotropic endocrine or inﬂammatory signals, nutritional components,
etc. But more importantly, it remains to be tested whether a determi-
nation of the Se to SELENOP ratio in human serum oﬀers additional
diagnostic, predictive or other health-related information on top of the
straight forward analysis of Se status by direct serum Se or SELENOP
quantiﬁcations. To this end, respective clinical analyses with high-
quality serum or plasma samples and employing validated quantiﬁca-
tion techniques with suitable standard reference materials are needed.
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